Nuvation Bio's EBIT per Share for the
three
months ended in Sep. 2024 was $-0.15.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.30.
During the past 3 years, the average EBIT per Share Growth Rate was -31.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Nuvation Bio's EBIT per Share or its related term are showing as below:
NUVB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.6 Med: -31.6 Max: -31.6
Current: -31.6
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Nuvation Bio was -31.60% per year. The lowest was -31.60% per year. And the median was -31.60% per year.
NUVB's 3-Year EBIT Growth Rate is ranked worse than 84.45% of 1222
companies
in the Biotechnology industry
Industry Median: 3.2
vs NUVB: -31.60
Nuvation Bio's EBIT for the
three
months ended in Sep. 2024 was $-41.09 Mil.
Nuvation Bio EBIT per Share Historical Data
The historical data trend for Nuvation Bio's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NYSE:NUVB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Nuvation Bio EBIT per Share Related Terms
Thank you for viewing the detailed overview of Nuvation Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB has been successfully added to your 